Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Adenocarcinoma D000230 166 associated lipids
Agranulocytosis D000380 7 associated lipids
Albuminuria D000419 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amnesia D000647 12 associated lipids
Anaphylaxis D000707 35 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Angina Pectoris D000787 27 associated lipids
Angina, Unstable D000789 14 associated lipids
Hypoxia D000860 23 associated lipids
Anthrax D000881 1 associated lipids
Arenaviridae Infections D001117 1 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arteriosclerosis Obliterans D001162 8 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthus Reaction D001183 8 associated lipids
Ascites D001201 25 associated lipids
Asphyxia Neonatorum D001238 4 associated lipids
Asthma D001249 52 associated lipids
Pulmonary Atelectasis D001261 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Birth Weight D001724 23 associated lipids
Blister D001768 16 associated lipids
Blood Platelet Disorders D001791 12 associated lipids
Body Weight D001835 333 associated lipids
Bovine Virus Diarrhea-Mucosal Disease D001912 2 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Brain Injuries D001930 4 associated lipids
Bronchial Diseases D001982 3 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchopulmonary Dysplasia D001997 4 associated lipids
Bronchopulmonary Sequestration D001998 3 associated lipids
Burns D002056 34 associated lipids
Burns, Inhalation D002059 4 associated lipids
Carbon Monoxide Poisoning D002249 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Central Nervous System Diseases D002493 10 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Cholecystitis D002764 8 associated lipids
Cholestasis D002779 23 associated lipids
Cholestasis, Intrahepatic D002780 4 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Cluster Headache D003027 4 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Colonic Diseases D003108 5 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Conjunctivitis D003231 7 associated lipids
Constriction, Pathologic D003251 8 associated lipids
Contracture D003286 3 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Coronary Disease D003327 70 associated lipids
Coronary Thrombosis D003328 7 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Death, Sudden D003645 12 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Dictyocaulus Infections D004022 1 associated lipids
Disseminated Intravascular Coagulation D004211 7 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dyslexia D004410 3 associated lipids
Ear Diseases D004427 7 associated lipids
Edema D004487 152 associated lipids
Encephalitis D004660 15 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Epilepsy D004827 35 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Escherichia coli Infections D004927 17 associated lipids
Extravasation of Diagnostic and Therapeutic Materials D005119 3 associated lipids
Fetal Growth Retardation D005317 9 associated lipids
Fever D005334 35 associated lipids
Fibrosis D005355 23 associated lipids
Gastritis D005756 27 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Glioma D005910 112 associated lipids
Gliosis D005911 6 associated lipids
Glomerulonephritis D005921 35 associated lipids
Glomerulonephritis, IGA D005922 7 associated lipids
Rhinitis, Allergic, Seasonal D006255 7 associated lipids
Heart Arrest D006323 13 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Cardiomegaly D006332 31 associated lipids
Heart Injuries D006335 6 associated lipids
Hematoma, Subdural D006408 3 associated lipids
Hemolysis D006461 131 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Chuang TT et al. High expression of beta-adrenergic receptor kinase in human peripheral blood leukocytes. Isoproterenol and platelet activating factor can induce kinase translocation. 1992 J. Biol. Chem. pmid:1339451
Jonas JM Triazolam and PAF inhibition. 1992 Lancet pmid:1345973
Kempe ER and Blank B Triazolam and PAF inhibition. 1992 Lancet pmid:1345974
Yan ZY et al. Platelet activating factor-induced changes in gastric motility and vascular resistance. 1992 Am. J. Surg. pmid:1346361
Sugiyama H et al. The effect of a selective alpha 2-adrenergic receptor antagonist (midaglizole) on the cyclic 3',5'-adenosine monophosphate production in human mononuclear cells. 1992 J. Allergy Clin. Immunol. pmid:1347546
Chaussade S et al. Paf-acether in stool as marker of intestinal inflammation. 1992 Lancet pmid:1347599
Benigni A et al. Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome. 1992 Lancet pmid:1347859
Richards B From proteins to protein interacting drugs. 1992 J. Pharm. Pharmacol. pmid:1348279
Thorne KJ et al. Increased binding of urease by activated eosinophils. Reassessment of an ELISA for CD11b. 1992 J. Immunol. Methods pmid:1349905
Martins MA et al. Interference of cetirizine with the late eosinophil accumulation induced by either PAF or compound 48/80. 1992 Br. J. Pharmacol. pmid:1350745
Kamei C et al. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (II). Antagonistic effect of epinastine on chemical mediators, mainly antihistaminic and anti-PAF effects. 1992 Immunopharmacol Immunotoxicol pmid:1350791
Calabresse C et al. Induction of high-affinity paf receptor expression during T cell activation. 1992 Eur. J. Immunol. pmid:1350980
Bodis J and Tinneberg HR Migraine. 1992 Lancet pmid:1351648
Le Gouvello S et al. CD2 triggering stimulates the formation of platelet-activating factor-acether from alkyl-arachidonoyl-glycerophosphocholine in a human CD4+ T lymphocyte clone. 1992 J. Immunol. pmid:1354232
Pinto A et al. Time course of PAF formation by gastrointestinal tissue in rats after castor oil challenge. 1992 J. Pharm. Pharmacol. pmid:1354728
Bienvenu K et al. Leukotriene B4 mediates shear rate-dependent leukocyte adhesion in mesenteric venules. 1992 Circ. Res. pmid:1355410
Kirsch CM et al. Mechanism of platelet activating factor-induced vascular leakage in the rat trachea. 1992 Jul-Aug Exp. Lung Res. pmid:1355425
Orallo F et al. Effects of platelet activating factor on contractions and 45Ca influx induced by noradrenaline and potassium in rat rubbed and intact aorta. Comparison with its hypotensive effect in anaesthetized normotensive rats. 1992 J. Pharm. Pharmacol. pmid:1355548
Castro-Faria-Neto HC et al. Interference of azelastine with anaphylaxis induced by ovalbumin challenge in actively sensitized rats. 1992 Eur. J. Pharmacol. pmid:1355732
Page C Asthma as a chronic inflammatory disease and the implications for future therapy. 1992 Ann Allergy pmid:1355953
Chihara J et al. Possible induction of intercellular adhesion molecule-1 (ICAM-1) expression on endothelial cells by platelet-activating factor (PAF). 1992 Jun-Jul J Lipid Mediat pmid:1356028
Narita S et al. [Effects of anti-PAF agents on nasal response after allergen challenge in guinea pigs]. 1992 Nippon Jibiinkoka Gakkai Kaiho pmid:1357119
Lustig HS et al. Comparative neurotoxic potential of glutamate, endothelins, and platelet-activating factor in cerebral cortical cultures. 1992 Neurosci. Lett. pmid:1357601
Juhlin L and Pihl-Lundin I Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects. 1992 Acta Derm. Venereol. pmid:1357858
Moritoki H et al. Involvement of nitric oxide pathway in the PAF-induced relaxation of rat thoracic aorta. 1992 Br. J. Pharmacol. pmid:1358382
Iwamoto I et al. Role of CD4+ T lymphocytes and interleukin-5 in antigen-induced eosinophil recruitment into the site of cutaneous late-phase reaction in mice. 1992 J. Leukoc. Biol. pmid:1358993
Mascolo N et al. Effects of senna and its active compounds rhein and rhein-anthrone on PAF formation by rat colon. 1992 J. Pharm. Pharmacol. pmid:1359100
Kleijnen J and Knipschild P Ginkgo biloba. 1992 Lancet pmid:1359218
Rachmilewitz D et al. Cytokines and platelet-activating factor in human inflamed colonic mucosa. 1992 Agents Actions pmid:1359744
Morley J Asthma mortality and inhaled beta agonist therapy. 1992 Aust N Z J Med pmid:1359864
Tsangaris GT et al. Study of the glycogenolytic action of platelet activating factor in Tetrahymena pyriformis. 1992 Comp. Biochem. Physiol. C, Comp. Pharmacol. Toxicol. pmid:1360357
Capasso F et al. PAF formation by human gastrointestinal mucosa/submucosa in-vitro: release by ricinoleic acid, and inhibition by 5-aminosalicylic acid. 1992 J. Pharm. Pharmacol. pmid:1360533
Spring J et al. Failure of salmeterol to inhibit circulating white cell responses and bronchoconstriction induced by platelet activating factor. 1992 Thorax pmid:1361250
Ramassamy C et al. The Ginkgo biloba extract, EGb761, increases synaptosomal uptake of 5-hydroxytryptamine: in-vitro and ex-vivo studies. 1992 J. Pharm. Pharmacol. pmid:1361545
Pasquale CP et al. Suppression by cetirizine of pleurisy triggered by antigen in actively sensitized rats. 1992 Eur. J. Pharmacol. pmid:1362160
Asako H et al. Phalloidin prevents leukocyte emigration induced by proinflammatory stimuli in rat mesentery. 1992 Am. J. Physiol. pmid:1362329
Nakajima H et al. CD4+ T-lymphocytes and interleukin-5 mediate antigen-induced eosinophil infiltration into the mouse trachea. 1992 Am. Rev. Respir. Dis. pmid:1362635
Chang TW et al. Blood levels of platelet-activating factor in endotoxin-sensitive and endotoxin-resistant mice during endotoxemia. 1992 J. Formos. Med. Assoc. pmid:1363632
May GR et al. The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit. 1991 Br. J. Pharmacol. pmid:1364849
Khanna A et al. Beneficial effects of intraluminal nitroglycerin in intestinal ischemia-reperfusion injury in rats. 2003 J. Surg. Res. pmid:13678693
Ichinose M et al. Activation of K+ current in macrophages by platelet activating factor. 1992 Biochem. Biophys. Res. Commun. pmid:1370616
Ziegler-Heitbrock HW et al. Gangliosides suppress tumor necrosis factor production in human monocytes. 1992 J. Immunol. pmid:1371788
McCormack DG et al. Bleomycin-induced lung injury in rats selectively abolishes hypoxic pulmonary vasoconstriction: evidence against a role for platelet-activating factor. 1992 Clin. Sci. pmid:1372199
Chanez P et al. [Mediators and neuromediators in asthma]. 1992 Presse Med pmid:1372975
Kunz D et al. The human leukocyte platelet-activating factor receptor. cDNA cloning, cell surface expression, and construction of a novel epitope-bearing analog. 1992 J. Biol. Chem. pmid:1374385
Lohde C et al. Influence of platelet activating factor antagonists on the protamine sulphate stimulated release of histamine from peritoneal mast cells of rats in vitro. 1992 Arzneimittelforschung pmid:1375025
Hines KL and Fisher RA Regulation of hepatic glycogenolysis and vasoconstriction during antigen-induced anaphylaxis. 1992 Am. J. Physiol. pmid:1375439
Block LH and Bühler FR Atherosclerosis, cell motility, calcium, and calcium-channel blockers. 1992 J. Cardiovasc. Pharmacol. pmid:1377297
Vieira LB et al. Angiogenic activity of PAF and inhibition of blood flow by Bothrops Jararaca venom in a mouse sponge model. 1992 EXS pmid:1377548
Zimmerman GA et al. Endothelial cell interactions with granulocytes: tethering and signaling molecules. 1992 Immunol. Today pmid:1377920
Bellan JA et al. Analysis of pulmonary and systemic vascular responses to platelet-activating factor in the cat. 1992 Am. J. Physiol. pmid:1379004
Nossaman BD et al. Blockade of thromboxane/endoperoxide receptor-mediated responses in the pulmonary vascular bed of the cat by sulotroban. 1992 Eur. J. Pharmacol. pmid:1379928
Pretolani M et al. Effect of human recombinant interleukin-5 on in vitro responsiveness to PAF of lung from actively sensitized guinea-pigs. 1992 Br. J. Pharmacol. pmid:1380388
Eliakim R and Rachmilewitz D Inflammatory mediators and the pathogenesis of inflammatory bowel disease. 1992 Jul-Aug Ital J Gastroenterol pmid:1381246
Tripathi YB et al. Involvement of tyrosine kinase and protein kinase C in platelet-activating-factor-induced c-fos gene expression in A-431 cells. 1992 Biochem. J. pmid:1382409
Andrade SP et al. Effects of platelet activating factor (PAF) and other vasoconstrictors on a model of angiogenesis in the mouse. 1992 Int J Exp Pathol pmid:1382541
Hayes JP et al. Involvement of inflammatory mediators in the airway responses to trimellitic anhydride in sensitized guinea-pigs. 1992 Br. J. Pharmacol. pmid:1382788
Yano S [Drug therapy of asthma by antiallergic agents]. 1992 Nippon Naika Gakkai Zasshi pmid:1383362
Massion PB and Frans A [Role of platelet activating factor and its antagonists in bronchial asthma]. 1992 Rev Pneumol Clin pmid:1384101
Asako H et al. Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. 1992 Transplantation pmid:1384191
Kimoto M et al. Dual effects of oleic acid on Ca2+ mobilization and protein phosphorylation in human platelets in presence or absence of platelet activating factor. 1992 Arch. Biochem. Biophys. pmid:1384432
Andrade SP et al. Effects of tumour cells on angiogenesis and vasoconstrictor responses in sponge implants in mice. 1992 Br. J. Cancer pmid:1384642
Martinez-Cuesta MA et al. The role of nitric oxide and platelet-activating factor in the inhibition by endotoxin of pentagastrin-stimulated gastric acid secretion. 1992 Eur. J. Pharmacol. pmid:1385169
Fumarola D and Pece S More on pathogenesis and treatment of septic shock. 1992 Eur. J. Epidemiol. pmid:1385209
Barrett KE Complex cellular recognition events in acute inflammation. 1992 Gastroenterology pmid:1385256
Konturek SJ et al. Role of platelet activating factor in pathogenesis of acute pancreatitis in rats. 1992 Gut pmid:1385272
Numao T and Agrawal DK Neuropeptides modulate human eosinophil chemotaxis. 1992 J. Immunol. pmid:1385521
Hood JS et al. Daltroban blocks thromboxane responses in the pulmonary vascular bed of the cat. 1992 J. Appl. Physiol. pmid:1385804
Okamoto H et al. Suppression of the Arthus reaction by Y-24180, a potent and specific antagonist of platelet-activating factor. 1992 Agents Actions pmid:1388318
Kitagawa S et al. Role of endogenous platelet-activating factor (PAF) in endotoxin-induced portal hypertension in rats. 1992 Sep-Oct J. Gastroenterol. Hepatol. pmid:1391729
Bernat A et al. Protective effect of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig. 1992 J Lipid Mediat pmid:1391738
Macpherson JL et al. Production and characterization of antibodies to platelet-activating factor. 1992 J Lipid Mediat pmid:1391739
Yang YQ et al. Binding of platelet-activating factor to oviductal membranes during early pregnancy in the rabbit. 1992 J Lipid Mediat pmid:1391740
Mathison R et al. Platelet activating factor and systemic anaphylaxis in Nippostrongylus brasiliensis-sensitized rats: differential effects of PAF antagonists. 1992 Br. J. Pharmacol. pmid:1393261
Shibuya H et al. Syntheses of a glycerophospholipid, C16-platelet activating factor and a palmitoyl analogue of M-5, an anti-inflammatory glyceroglycolipid. 1992 Chem. Pharm. Bull. pmid:1394629
Iwakami S et al. Platelet activating factor (PAF) antagonists contained in medicinal plants: lignans and sesquiterpenes. 1992 Chem. Pharm. Bull. pmid:1394633
Yoshikawa D and Goto F Effect of platelet-activating factor antagonist and leukotriene antagonist on endotoxin shock in the rat: role of the leukocyte. 1992 Circ. Shock pmid:1394861
Chang SW Endotoxin-induced lung vascular injury: role of platelet activating factor, tumor necrosis factor and neutrophils. 1992 Clin Res pmid:1395440
Taniguchi H et al. Role of platelet-activating factor in pulmonary edema after coronary ligation in dogs. 1992 Chest pmid:1395776
Sobhani I et al. Significance and regulation of gastric secretion of platelet-activating factor (PAF-acether) in man. 1992 Dig. Dis. Sci. pmid:1396006
Friedman M et al. Effects of ozone exposure on lipid metabolism in human alveolar macrophages. 1992 Environ. Health Perspect. pmid:1396473
Pretolani M et al. Inhibition by azelastine of the effects of platelet-activating factor in lungs from actively sensitised guinea-pigs. 1992 Eur. J. Pharmacol. pmid:1397002
Herbert JM et al. Effect of SR 27417 on oedema formation induced in rabbit skin by platelet-activating factor or antigen. 1992 Eur. J. Pharmacol. pmid:1397004
Hogaboam CM et al. PF-5901 inhibits gastrointestinal platelet-activating factor synthesis in vivo. 1992 Eur. J. Pharmacol. pmid:1397016
Ono S et al. PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats. 1992 J. Appl. Physiol. pmid:1400021
Davidson D and Drafta D Prolonged pulmonary hypertension caused by platelet-activating factor and leukotriene C4 in the rat lung. 1992 J. Appl. Physiol. pmid:1400062
Lee TC et al. A novel CoA-independent transacetylase produces the ethanolamine plasmalogen and acyl analogs of platelet-activating factor (PAF) with PAF as the acetate donor in HL-60 cells. 1992 J. Biol. Chem. pmid:1400315
Girotra NN et al. Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)-phenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent orally active platelet-activating factor (PAF) antagonist and its water-soluble prodrug phosphate ester. 1992 J. Med. Chem. pmid:1404229
Mariano F et al. Role of alpha 1-proteinase inhibitor in restraining peritoneal inflammation in CAPD patients. 1992 Kidney Int. pmid:1405351
Kraut JA et al. Platelet-activating factor attenuates the arginine vasopressin-induced fall of transepithelial resistance across inner medullary collecting duct monolayers. 1992 Miner Electrolyte Metab pmid:1406507
Radeau T et al. Enhanced esterification process of 5-hydroxyeicosatetraenoic acid (5-HETE) in PMN from asthmatic patients. 1992 Prostaglandins pmid:1410523
Csáki C et al. Role of platelet-activating factor in the development of endothelial dysfunction in hemorrhagic hypotension and retransfusion. 1992 Thromb. Res. pmid:1412179
Wong CW et al. Comparative effects of tetrandrine and berbamine on subcutaneous air pouch inflammation induced by interleukin-1, tumour necrosis factor and platelet-activating factor. 1992 Agents Actions pmid:1414679
Tran A et al. Separate induction of human blood platelet aggregation or cytotoxicity by different concentrations of PAF-acether and thrombin. 1992 Agents Actions pmid:1414687
Prescott SM What are the effects of dietary fatty acid modification on platelet eicosanoid metabolism, platelet-activating factor, and platelet function? How might these metabolic alterations influence thrombosis? 1992 Am. J. Clin. Nutr. pmid:1414987
Duque I et al. Effects of reactive oxygen species on cultured rat mesangial cells and isolated rat glomeruli. 1992 Am. J. Physiol. pmid:1415575
Kruse-Elliott KT et al. Differential effects of WEB 2086 and SRI 63-441 on TNF-alpha-induced alterations in cardiopulmonary function. 1992 Am. J. Physiol. pmid:1415600
Milhoan KA et al. Hypoxia induces endothelial cells to increase their adherence for neutrophils: role of PAF. 1992 Am. J. Physiol. pmid:1415623
Dorn GW and Davis MG Differential megakaryocytic desensitization to platelet agonists. 1992 Am. J. Physiol. pmid:1415671
Faden AI and Tzendzalian PA Platelet-activating factor antagonists limit glycine changes and behavioral deficits after brain trauma. 1992 Am. J. Physiol. pmid:1415805